Breast sharing for closure contralateral mastectomy defect

2018 ◽  
Vol 2 ◽  
pp. 11-11
Author(s):  
Prakasit Chirappapha ◽  
Rupporn Sukpanich ◽  
Monchai Leesombatpaiboon ◽  
Chairat Supsamutchai ◽  
Thongchai Sukarayothin ◽  
...  
Keyword(s):  
Contralateral Mastectomy

scholarly journals Clinicopathologic Profile of Breast Cancer in Germline ATM and CHEK2 Mutation Carriers

Genes ◽  
2021 ◽  
Vol 12 (5) ◽  
pp. 616
Author(s):  
Angela Toss ◽  
Elena Tenedini ◽  
Claudia Piombino ◽  
Marta Venturelli ◽  
Isabella Marchi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
High Rate ◽  
Luminal A ◽  
Clinicopathologic Characteristics ◽  
Luminal B ◽  
Chek2 Mutation ◽  
Mutation Carriers ◽  
Clinicopathologic Profile ◽  
Contralateral Mastectomy

The most common breast cancer (BC) susceptibility genes beyond BRCA1/2 are ATM and CHEK2. For the purpose of exploring the clinicopathologic characteristics of BC developed by ATM or CHEK2 mutation carriers, we reviewed the archive of our Family Cancer Clinic. Since 2018, 1185 multi-gene panel tests have been performed. Nineteen ATM and 17 CHEK2 mutation carriers affected by 46 different BCs were identified. A high rate of bilateral tumors was observed in ATM (26.3%) and CHEK2 mutation carriers (41.2%). While 64.3% of CHEK2 tumors were luminal A-like, 56.2% of ATM tumors were luminal B-like/HER2-negative. Moreover, 21.4% of CHEK2-related invasive tumors showed a lobular histotype. About a quarter of all ATM-related BCs and a third of CHEK2 BCs were in situ carcinomas and more than half of ATM and CHEK2-related BCs were diagnosed at stage I-II. Finally, 63.2% of ATM mutation carriers and 64.7% of CHEK2 mutation carriers presented a positive BC family history. The biological and clinical characteristics of ATM and CHEK2-related tumors may help improve diagnosis, prognostication and targeted therapeutic approaches. Contralateral mastectomy should be considered and discussed with ATM and CHEK2 mutation carriers at the first diagnosis of BC.

scholarly journals Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis

BMJ ◽  
2014 ◽  
Vol 348 (feb11 9) ◽  
pp. g226-g226 ◽  
Author(s):  
K. Metcalfe ◽  
S. Gershman ◽  
P. Ghadirian ◽  
H. T. Lynch ◽  
C. Snyder ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Retrospective Analysis ◽  
Brca1 And Brca2 ◽  
Brca2 Mutations ◽  
Contralateral Mastectomy ◽  
Brca1 And Brca2 Mutations

Contralateral mastectomy in young women with breast cancer: A population-based analysis of predictive factors and clinical impact.

2014 ◽  
Vol 32 (26_suppl) ◽  
pp. 82-82
Author(s):  
Antoine Bouchard-Fortier ◽  
Nancy N. Baxter ◽  
Kimberley Fernandes ◽  
Ximena Camacho ◽  
May Lynn Quan
Keyword(s):  
Breast Cancer ◽  
Young Women ◽  
Invasive Breast Cancer ◽  
Survival Benefit ◽  
Estrogen Receptor Status ◽  
Population Based ◽  
Lymph Node Status ◽  
P Value ◽  
Significant Survival ◽  
Contralateral Mastectomy

82 Background: Contralateral mastectomy (CM) has recently been shown to be associated with survival benefit in women with breast cancer. The objectives of the present study were to describe factors predictive of CM in young women (≤35 years old) with invasive breast cancer and evaluate its impact on survival, in a large population based cohort. Methods: All women diagnosed with invasive breast cancer aged ≤35 from 1994 – 2003 treated with mastectomy were identified from the Ontario Cancer Registry. Patient demographics, complete tumour and treatment characteristics were abstracted from primary chart review. Cox proportional hazard regression was performed to assess factors associated with performance of CM and its effect on recurrence and overall survival, performance of CM was modeled as a time varying co-variate. The models were controlled for known predictors including age, tumor size, nodal status, ER/PR, LVI, histologic grade, systemic therapy and adjuvant radiation. Results: There were 628 women identified. Of these, 101 underwent a CM (16.1%). On multivariable analysis, factors predictive of CM were negative lymph node status (HR: 1.74, 95% CI [1.052-2.872]; p-value = 0.031) and negative estrogen receptor status (HR: 2.7, 95% CI [1.314-5.736]; p-value = 0.007). After a median follow up of 11 years, no significant survival benefit was observed in women undergoing CM compared to those who did not (HR: 0.95, 95% CI [0.61-1.46], p-value = 0.80). Conclusions: Performance of CM in young women with invasive breast cancer did not result in a significant survival benefit, compared to those without CM. Factors found to be predictive of performance of CM negative lymph node status and negative estrogen receptor status. Further studies are needed to determine if a subset of young women might benefit from CM.

Contralateral mastectomy in patients treated for unilateral breast cancer

2009 ◽  
Vol 1 (2) ◽  
pp. 104-109
Author(s):  
Kandace P. McGuire ◽  
M. Catherine Lee ◽  
Christine Laronga
Keyword(s):  
Breast Cancer ◽  
Unilateral Breast Cancer ◽  
Contralateral Mastectomy
Sign in / Sign up

Export Citation Format

Share Document